Scarica l'app Stockscreener
412.84
1.13%
-4.73
Dopo l'orario di chiusura:
412.84
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$417.57
Aprire:
$420.34
Volume 24 ore:
2.27M
Relative Volume:
0.89
Capitalizzazione di mercato:
$223.19B
Reddito:
$37.30B
Utile/perdita netta:
$7.80B
Rapporto P/E:
28.71
EPS:
14.3793
Flusso di cassa netto:
$8.60B
1 W Prestazione:
+2.54%
1M Prestazione:
+9.41%
6M Prestazione:
+18.01%
1 anno Prestazione:
+41.19%
Intervallo 1D:
$411.04
$420.35
Intervallo di 1 settimana:
$400.06
$420.35
Portata 52W:
$288.00
$447.03
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
412.84 | 223.19B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,166.51 | 1.04T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
248.61 | 599.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
274.36 | 484.83B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
141.98 | 350.29B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
142.41 | 270.68B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-08 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2026-08-05 | Reiterato | BMO Capital Markets | Outperform |
| 2026-08-05 | Reiterato | BofA Securities | Underperform |
| 2026-08-05 | Reiterato | Canaccord Genuity | Hold |
| 2026-08-05 | Reiterato | Morgan Stanley | Equal-Weight |
| 2026-08-05 | Reiterato | Oppenheimer | Outperform |
| 2026-08-05 | Reiterato | RBC Capital Mkts | Outperform |
| 2026-08-05 | Reiterato | Robert W. Baird | Underperform |
| 2026-08-05 | Reiterato | Truist | Hold |
| 2026-08-05 | Reiterato | Wells Fargo | Equal Weight |
| 2026-05-05 | Downgrade | Erste Group | Buy → Hold |
| 2026-04-21 | Iniziato | Canaccord Genuity | Hold |
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
J&J Q3 Earnings Beat Estimates, Sales Miss, View Raised, Stock Down - Zacks Investment Research
Here's Why Amgen (AMGN) is a Strong Momentum Stock - Zacks Investment Research
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? - The Motley Fool
How Much Would You Need to Invest in These 5 Pharma Stocks to Earn $1,000 a Month in Dividends? - The Motley Fool
Amgen (AMGN) Laps the Stock Market: Here's Why - Zacks Investment Research
A Stock Market Crash Is Coming By the End of 2027, According to Some Economists. Here Are 2 Stocks to Buy Before That Happens - The Motley Fool
J&J Stock Ahead of Q3 Earnings: Should You Buy, Sell or Hold? - Zacks Investment Research
Stock Market News for Oct 8, 2026 - Zacks Investment Research
Amgen (AMGN) Advances While Market Declines: Some Information for Investors - Zacks Investment Research
Can Amgen (NASDAQ:AMGN) Win With Direct-to-Patient Access Programs? - Kalkine Media
3,524 Amgen Inc. $AMGN Shares Sold by Colton Groome Financial Advisors LLC - MarketBeat
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Zacks Investment Research
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance UK
Amgen Inc. $AMGN Shares Purchased by MassMutual Private Wealth & Trust FSB - MarketBeat
Amgen Inc. $AMGN Shares Purchased by Ferguson Wellman Capital Management Inc. - MarketBeat
2,546 Amgen Inc. $AMGN Shares Sold by Argent Capital Management LLC - MarketBeat
AMGEN INC. R (AMG.MU) Q2 FY2026 earnings call transcript - Yahoo Finance
Cantor Fitzgerald reiterates Amgen stock Neutral rating at $400 By Investing.com - Investing.com India
Is AMGN Overvalued? DCF Says Worth $189 - GuruFocus
Amgen Inc Stock Futures,Dec-202 (SAMGN=F) Interactive Stock Chart - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Sold by CX Institutional - MarketBeat
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Ohio Rep. David Taylor Bought Up to $45K Worth of Amgen Stock - benzinga.com
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Inc Investor Call At IASLC 2019 World Conference on Lung Cancer Transcript - GuruFocus
Amgen Inc Stock (AMGN) Closed Down by 3.38% on Oct 1: What Investors Need To Know - TradingKey
Amgen Inc (AMGN) Shares Fall 3.4% -- GF Value Says Still Overval - GuruFocus
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Zacks Investment Research
Amgen (AMGN) Stock Dips While Market Gains: Key Facts - Yahoo Finance
More Than Skin Deep: Understanding Discoid Lupus Erythematosus - Amgen
Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win - Zacks Investment Research
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight - GlobeNewswire Inc.
Amgen Readies Daxdilimab For Phase III In Discoid Lupus After Mid-Stage Trial - insights.citeline.com
Homozygous Familial Hypercholesterolemia (HoFH)7MM Market, Epidemiology, and Forecast2036 | RNAi and Targeted Therapies Expand Uptake and Investment Opportunities - GlobeNewswire Inc.
Bone Metastasis in Solid Tumors Market Insights, Epidemiology, and 7MM Forecast2036 | Precision Oncology and Radiopharmaceuticals Unlock New Growth Opportunities - GlobeNewswire Inc.
Amgen reveals 6-point drop in lupus severity behind phase 2 win for Horizon antibody - Fierce Biotech
Amgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells Investors - GuruFocus
Amgen Inc. stock outperforms competitors on strong trading day - marketwatch.com
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen (NASDAQ:AMGN) Stock: Dazodalibep's Phase 3 Win Targets a Disease With No Approved Medicines - kalkine.ca
Amgen Inc Agencies, 2017 - OpenSecrets
Amgen (NASDAQ:AMGN) Reports Positive Dazodalibep Data in Sjogren's - Kalkine Media
AMGN Maintains Rating by Scotiabank -- Price Target Raised to $5 - GuruFocus
Scotiabank maintains Sector Outperform rating on Amgen, $500 price target - tradingview.com
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - Yahoo Finance
Why Amgen’s 6% Dividend Raise Masks a Tougher Road Ahead - 24/7 Wall St.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth? - Yahoo Finance
Amgen (AMGN), What Is Behind The Fresh Attention? - Yahoo Finance
News | Amgen’s sale-leaseback with Mesirow ranks among largest recent office deals in Chicago suburbs - CoStar
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Amgen Inc Azioni (AMGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
| Khosla Rachna | Officer |
Aug 13 '26 |
Proposed Sale |
412.76 |
1,252 |
516,775 |
0 |
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | Officer |
Aug 11 '26 |
Proposed Sale |
414.21 |
2,000 |
828,420 |
0 |
| Derek Miller | Officer |
Aug 06 '26 |
Proposed Sale |
404.85 |
3,890 |
1,574,866 |
0 |
| Grygiel Nancy A. | Officer |
Aug 06 '26 |
Proposed Sale |
447.17 |
2,670 |
1,193,940 |
0 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Option Exercise |
177.41 |
2,970 |
526,906 |
9,310 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Option Exercise |
169.56 |
3,890 |
659,574 |
14,531 |
| Miller Derek | SVP, Human Resources |
Aug 06 '26 |
Sale |
402.54 |
3,890 |
1,565,898 |
12,462 |
| Grygiel Nancy A. | SVP & CCO |
Aug 06 '26 |
Sale |
402.16 |
2,970 |
1,194,415 |
7,340 |
1.59%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):